Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: jpbrody who wrote (399)	7/31/1998 9:53:00 AM
From: John Zwiener	Read Replies (1) \| Respond to of 1025

jpbrody, thanks for that extensive post. If Roche buyout the license for central labs, then they would own it for that purpose, an exclusive license. Total immunoassay testing is over 6 billion. I don't know what proportion of that is POC, but it is very small. However, there haven't been adequate instruments to run these tests till very recently. Glucose monitering is beginning to move to hospital floors, and is successful. Electrolyte monitering (i-stat) is not as useful and is too expensive. Immunoassays can be vital is some circumstances, and the faster, the better. There is a lot of interest in POC for MI markers. The margin for central labs is relatively small compared to the other areas. I think the POC, HTP, food and water testing, industrial,vet, etc are together much bigger than the Roche license.